Skip to main
TMO
TMO logo

TMO Stock Forecast & Price Target

TMO Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 25%
Buy 63%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Thermo Fisher Scientific is projected to experience stable revenue growth across its various segments, with lab products and services (LPBS) expected to increase at a compound annual growth rate of 5.4% over the next three years. The company is anticipated to capitalize on favorable trends in biopharma clinical trial outsourcing, as survey respondents indicated a significant intention to increase outsourcing in both early-stage and late-stage drug development. Additionally, analytical instruments revenue is forecasted to grow at a compound annual rate of 2.5%, reflecting the company's continued strategic positioning and competitive advantages within its market segments.

Bears say

Thermo Fisher Scientific has experienced a substantial decline in its adjusted EBIT margin, dropping approximately 830 basis points to 22.6% from 2021 to 2024. This downturn is attributed to a significant reduction in the adjusted gross margin, which decreased by about 940 basis points to 42.2%, and is approximately 420 basis points lower than the gross margin recorded in 2019. The deterioration in these key financial metrics indicates fundamental challenges within the company's operations, contributing to a negative outlook for its stock.

TMO has been analyzed by 16 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 63% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Thermo Fisher Scientific (TMO) Forecast

Analysts have given TMO a Buy based on their latest research and market trends.

According to 16 analysts, TMO has a Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $611.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $611.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Thermo Fisher Scientific (TMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.